- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- December 2020
Comments
RED1,8: NICE TA658: Isatuximab with pomalidomide and dexamethasone, for
treatment of relapsed and refractory multiple myeloma. (Decision date - December 2020)
DO NOT PRESCRIBE (DNP)6: NICE TA727 - Isatuximab with carfilzomib and dexamethasone for treating
relapsed or refractory multiple myeloma (terminated appraisal) (Decision date - Oct 2021)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again